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Abstract 
Life sciences are currently at the centre of an information revolution. The nature and amount of information now available opens up areas 
of research that were once in the realm of science fiction. During this information revolution, the data-gathering capabilities have greatly 
surpassed the data-analysis techniques. Data integration across heterogeneous data sources and data aggregation across different 
aspects of the biomedical spectrum, therefore, is at the centre of current biomedical and pharmaceutical R&D. 
This paper reports on original results from the ACGT integrated project, focusing on the design and development of a European 
Biomedical Grid infrastructure in support of multi-centric, post-genomic clinical trials (CTs) on cancer. Post-genomic CTs use multi-level 
clinical and genomic data and advanced computational analysis and visualization tools to test hypotheses in trying to identify the 
molecular reasons for a disease and the stratification of patients in terms of treatment. 
The paper provides a presentation of the needs of users involved in post-genomic CTs and presents indicative scenarios, which drive the 
requirements of the engineering phase of the project. Subsequently, the initial architecture specified by the project is presented, and its 
services are classified and discussed. A range of such key services, including the Master Ontology on sCancer, which lie at the heart of 
the integration architecture of the project, is presented. Special efforts have been taken to describe the methodological and technological 
framework of the project, enabling the creation of a legally compliant and trustworthy infrastructure. Finally, a short discussion of the 
forthcoming work is included, and the potential involvement of the cancer research community in further development or utilization of the 
infrastructure is described. 
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Introduction 
Life sciences are currently at the centre of an information 
revolution. Dramatic changes are being registered as a 
consequence of the development of techniques and tools that 
allow the collection of biological information at an 
unprecedented level of detail and in extremely large quantities. 
Advanced technologies, such as high-throughput screening, 
genomics, proteomics and metabonomics, have resulted in data 
generation on a previously unknown scale. 
The nature and amount of information now available opens up 
areas of research that were once in the realm of science fiction. 
Pharmacogenomics [1], diagnostics [2] and drug target 
identification [3] are just a few of the many areas that have the 
potential to use this information to change dramatically the 
scientific landscape in the life sciences. 
During this information revolution, the data-gathering 
capabilities have greatly surpassed the data-analysis 
techniques. If we were to imagine the Holy Grail of life sciences, 
we might envision a technology that would allow us to fully 
understand the data at the speed at which these are collected. 
Sequencing, localization of new genes, functional assignment, 
pathway elucidation and understanding the regulatory 
mechanisms of the cell and organism should be easy. Ideally, 
we would like knowledge manipulation to become as efficient as 
goods manufacturing is today: highly automated, producing 
more goods, of higher quality and in more cost-effective manner 
than manual production. It is our belief that, in a sense, 
knowledge manipulation is now reaching its pre-industrial age. 
The explosive growth in the number of new and powerful 
technologies within proteomics and functional genomics can 
now produce massive amounts of data, but using it to 
manufacture highly processed pieces of knowledge still requires 
skilled elaborate involvement of experts to forge through small 
pieces of raw data one at a time. The ultimate challenge in the 
coming years, we believe, will be to automate this knowledge 
discovery process. 
Therefore, data integration across heterogeneous data sources 
and data aggregation across different aspects of the biomedical 
spectrum is at the centre of current biopharmaceutical R&D. A 
technological infrastructure supporting such a knowledge 
discovery process should, ideally, allow for: 
1.  Data to be searched, queried, extracted, integrated and 
shared in a scientifically and semantically consistent 
manner across heterogeneous sources, both public and 
proprietary, ranging from chemical structures and omics to 
clinical trials data. 
2.  Discovery and invocation of scientific tools that are shared 
by the community, rather than repeatedly developed by 
each and every organization that needs to analyse their 
data. 
3.  Apart from the sharing of tools, it should also allow for their 
integration as modules in a generic framework and applied 
to relevant dynamic datasets. We refer to this process as 
’discovery driven scientific workflows‘, which ideally would 
also be executed in a fast, unsupervised manner. 
 
Needless to say, our current inability to efficiently share data 
and tools in a secure and efficient way is severely hampering 
the research process. The objective of the Advancing Clinico-
Genomic Trials on Cancer (ACGT) Project is to contribute to the 
resolution of these problems through the development of a 
unified technological infrastructure, which will facilitate the easy 
and secure access and analysis, of multi-level clinical and 
genomic data enriched with high-performing knowledge 
discovery operations and services in support of multi-centric, 
post-genomic clinical trials (see Figure 1). 
This paper presents a short background section discussing the 
urgent needs faced by the biomedical informatics research 
community, and very briefly describes the clinical trials upon 
which the ACGT project is based for both gathering and eliciting 
requirements and also for validating the technological 
infrastructure designed. It continues with a presentation of the 
initial ACGT architecture and presents its layers and key 
enabling services. The rest of the paper is focused on the 
functional description of key services that jointly create the 
integrated technological infrastructure of ACGT, supporting 
easy data integration and knowledge discovery. The final 
section critically discusses open issues and particularly focuses 
on the issue of community involvement. It presents ways in 
which such involvement may be fostered by the project. 
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Figure 1: The envisaged ACGT problem-solving environment supporting integrated access and analysis of multi-level, heterogeneous and 
distributed biomedical data. 
 
Post-genomic clinical trials on cancer 
In ACGT, we focus on the domain of clinical trials on cancer. It 
is well established that patient recruitment is often the time-
limiting factor for clinical trials. As a result, clinical trials are 
gradually turning multi-centric to limit the time required for their 
execution [4]. 
Also, with respect to cancer research, the use of high-
throughput technologies has resulted in an explosion of 
information and knowledge about cancers and their treatment. 
Cancer, being a complex multi-factorial disease group that 
affects a significant proportion of the population worldwide, is a 
prime target for focused multi-disciplinary efforts using these 
novel and powerful technologies [2]. Exciting new research on 
the molecular mechanisms that control cell growth and 
differentiation has resulted in a quantum leap in our 
understanding of the fundamental nature of cancer cells. 
While these opportunities exist, the lack of a common 
infrastructure has prevented clinical research institutions from 
being able to mine and analyse disparate, multi-level data 
sources. As a result, very few cross-site studies and multi-
centric clinical trials are performed, and in most cases, it is not 
possible to easily integrate multi-level data (from the molecular 
to the organ and individual levels). 
The ACGT project has been structured within such a context. It 
has selected two cancer domains and has defined three specific 
trials. These trials serve a dual purpose. Firstly, they are used 
for developing a range of post-genomic analytical scenarios to 
feed the requirement analysis and elicitation phase of the 
project, and secondly, they will be used for the validation of the 
functionality of the ACGT technologies. 
The ACGT trials are in the domain of breast cancer and Wilm's 
tumour (pediatric nephroblastoma). Specifically: 
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1. The ACGT test of principle (TOP) study aims to identify 
biological markers associated with pathological complete 
response to anthracycline therapy (epirubicin), one of the most 
active drugs used in breast cancer treatment [5]. 
2. Wilms' tumour, although rare, is the most common primary 
renal malignancy in children and is associated with a number of 
congenital anomalies and documented syndromes. 
The goal of the current clinical trial is to reduce therapy for 
children with low-risk tumours, thereby avoiding acute and long-
term toxicities. Challenges remain in identifying novel molecular, 
histological and clinical risk factors for stratification of treatment 
intensity. This could allow a safe reduction in therapy for 
patients known to have an excellent chance of cure with the 
current therapy, while identifying, at diagnosis, the minority of 
children at risk of relapse, who will require more aggressive 
treatments [6]. 
In addition to these trials, and on the basis of data collected for 
the purpose of their execution, an in silico modelling and 
simulation experiment is also planned. The aim of this 
experiment is to provide clinicians with a decision support tool 
able to simulate, within defined reliability limits, the response of 
a solid tumour to therapeutic interventions based on the 
individual patient's multi-level data. The most critical biological 
phenomena (e.g. metabolism, cell cycling, geometrical growth 
or shrinkage of the tumour, cell survival, following irradiation or 
chemotherapeutic treatment, necrosis, apoptosis) will be thus 
spatiotemporally simulated using a variety of clinical, 
radiobiological, pharmacodynamic, molecular and imaging data 
[7]. 
For a more elaborate description of these trials, readers are 
referred to [8]. 
 
Technical challenges 
The ACGT's vision is to become a pan-European voluntary 
network connecting individuals and institutions and to enable 
the sharing of data and tools (see Figure 2). In order to achieve 
its goals and objectives, ACGT is creating an infrastructure for 
cancer research by using a virtual web of trusted and 
interconnected organizations and individuals to leverage the 
combined strengths of cancer centres and investigators and 
enable the sharing of biomedical cancer-related data and 
research tools in such a way that the common needs of 
interdisciplinary research are met and tackled. 
Considering the current size of clinical trials (hundreds of 
patients), there is a clear need, both from the viewpoint of the 
fundamental research and from that of the treatment of 
individual patients, for a data analysis environment that allows 
the exploitation of this enormous pool of data [9]. 
A major part of the project is devoted to research and 
development in infrastructure components that are gradually 
being integrated into a workable demonstration platform upon 
which the selected (and those to be selected during the lifecycle 
of the project) clinical studies will be demonstrated and 
evaluated against user requirements defined at the onset of the 
project. 
 
Scientific and functional requirements 
The real and specific problem that underlies the ACGT concept 
is coordinated resource sharing and problem solving in 
dynamic, multi-institutional, pan-European virtual organizations. 
A set of individuals and/or organizations defined by such 
sharing relationships form what we call ‘an ACGT virtual 
organization’ (VO) [10]. Simply stated, the participants in a 
multi-centric clinical trial form a VO, which exists for the duration 
of a trial or for any other period of time based on mutual 
agreements. 
The task, therefore, of ACGT is to make data and tools securely 
available in this inter-enterprise environment, where and when 
needed, to all authorized users. As a result, the scientific and 
functional requirements for the ACGT platform can be 
summarized as follows: 
1.  Virtual organization management: support for the dynamic 
creation of VOs, defined as a group of individuals or institutions 
who share the computing and other resources of a ‘grid’ for a 
common goal. 
2. Data federation: seamless navigation across and access to 
heterogeneous data sources, both private and public. 
3.  Data integration: the capacity to pool data from 
heterogeneous sources in a scientifically, semantically and 
mathematically consistent manner for further computation. 
4. Shared services: the development, sharing and integration of 
relevant and powerful data exploitation tools such as tools for 
bioinformatics analysis, data mining, modelling and simulation. 
The requirements for the elicitation process that has taken place 
in the project, based on input for a diverse range of users, has 
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Figure 2: The vision of ACGT. Creating and managing virtual organizations on the grid who are jointly participating in the execution of clinical 
trials and who decide to adopt the principles of sharing of both data and tools. 
 
resulted in the identification of the following key technical 
requirements: 
1. Flexibility: in other words, modularity (supporting integration 
of new resources in a standardized way) and configurability 
(accommodating existing and emerging needs). This is required 
because (a) The a priori scientific and functional requirements 
are broad and diverse; (b) the data resources to be federated by 
the ACGT platform are characterized by deep heterogeneities in 
terms of source, ownership, availability, content, database 
design, data organization, semantics and so on; and (c) the 
complexity of the underlying science, as well as the complexity 
of applicable knowledge representation schemas and applicable 
scientific algorithms. 
2. Intuitive access to information: from the user's point of view, 
the ACGT knowledge management platform must provide 
relevant and simple access to information—both in terms of 
searching and navigation—and to services. In addition, it must 
provide a dynamically evolving set of validated data exploration, 
analysis, simulation and modelling services. 
3.  Security: finally, it must be consistent with the European 
ethical and legal framework, providing a high degree of trust 
and security to its users. 
Evaluation scenarios 
We have adopted a scenario-based development process. A 
range of scenarios, that is the tasks users want to perform, 
structured and described as a sequence of activities that require 
access to heterogeneous data, use of various tools for its 
analysis and invocation of appropriate tools for visualizing and 
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Figure 3: The ACGT layered architecture and its main services. 
interpreting the results, have been defined by the ACGT user 
community. 
These scenarios cover the most important functional goals of 
the infrastructure. In practice, the following fields are covered: 
1.  Administrative scenarios related to the setup and 
maintenance of the infrastructure, such as integration of 
databases. 
2. Administrative scenarios related to the management of users 
and institutions in the context of virtual organizations. 
3. Technological  scenarios,  validating the integration of data 
analysis tools per se (e.g. R) and their integration with clinical 
data. 
4.  Clinical-oriented scenarios, validating the analysis tools as 
used by clinicians and biomedical researchers in realistic 
contexts. 
5.  Meta-analysis scenarios, validating the use of ACGT as 
clinical-research validation tool. 
Space does not allow for a detailed description of these 
scenarios. Interested readers should access the project 
website, where relevant information will be available soon in the 
project's quarterly Newsletter. 
 
The ACGT architecture and services 
In principle, the requirements for the ACGT platform can be met 
by designing a federated environment articulating independent 
tools, components and resources based on open architectural 
standards, which is customizable and capable of dynamic 
reconfiguration. 
Considering that the amount of data generated in the context of 
post-genomic clinical trials is expected to rise to several 
gigabytes of data per patient in the near future, access to high-
performance computing resources will be unavoidable. Hence, 
grid computing [11] appears to be a promising technology. 
Access and use of grid-based resources is thus an integral part 
of the design of the infrastructure. 
A layered approach has been selected for providing different 
levels of abstraction and a classification of functionality into 
groups of homologous software entities [12]. In this approach, 
we consider the security services and components to be 
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Figure 4: Simplified ACGT architecture assumed in the context of the present document. Data are made available for federated access to an 
ACGT virtual organization, following anonymization (CAT tool); data access is only permitted to authorized members of an ACGT virtual 
organization through the use of appropriate services (GAS—Gridge Authorisation Service). 
pervasive throughout ACGT so as to provide both for the user 
management, access rights management and enforcement, and 
trust bindings that are facilitated by the grid and domain-specific 
security requirements like pseudonymization and 
anonymization. 
In specifying the initial architecture of the ACGT technological 
platform, architectural specifications of other relevant projects 
have been thoroughly studied. Of particular relevance are the 
Cancer Biomedical Informatics Grid (caBIG) [13] in the United 
States and the CancerGrid [14] Project in the United Kingdom. 
The overall approach in these projects is somewhat different 
from the one in ACGT. In caBIG, the bottom-up, technology-
oriented approach was chosen, in which the focus was put on 
the integration of a large number of analytical tools but with 
weak concern on data-privacy issues. CancerGrid on the other 
hand addresses the specific needs of the British clinical 
community. As a result, some aspects of the project may not 
fully overlap with the European and international scope of 
ACGT. 
The ACGT environment is designed to be versatile and will 
allow the integration of high-throughput databases with data 
both from existing (e.g. microarrays, imaging) and future 
technologies (e.g. high-throughput proteomics). The design of 
the platform considers the integration of private (i.e. trial-
specific) databases with public ones, thus potentially making 
public datasets immediately available for hypothesis validation 
and meta-analyses. An overview of the ACGT system layered 
architecture is given in Figure 3. The various layers of the 
architecture are briefly described in the following. For a more 
detailed description, the reader is referred to [9, 12]. 
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Of particular importance is the security layer of the architecture; 
access rights, security (encryption) and trust building are issues 
addressed and solved on this layer, based on system 
architectural and security analysis [15]. Also, domain-specific 
security services, such as pseudo-anonymization and 
anonymization services (CAT in Figure 4) are modelled and 
invoked through this layer (see section ‘The ACGT security 
Framework’). 
In subsequent sections we describe, in slightly more details, the 
Bioinformatics and Knowledge Discovery Services, which 
represent the ‘workhorse’ of ACGT and the corresponding layer 
is the place where the majority of ACGT specific services lie. 
Some characteristic examples of such key services are the (a) 
Mediator Services that offer uniform access to distributed and 
heterogeneous clinical trial and other post-genomic biomedical 
databases; (b) Ontology Services that provide a 
conceptualisation of the domain through the Master Ontology on 
Cancer and the ‘domain of discourse’ for constructing complex 
queries for the mediator services; (c) Workflow Enactment 
Services that support the efficient management and execution 
of complex biomedical workflows; (d) Metadata Repositories 
and the corresponding services for the persistent management 
of services' metadata descriptions; and (e) an assortment of 
data mining and knowledge discovery tools and services that 
fulfil the data analysis requirements of ACGT. 
Validation of the initial architecture 
Anticipated scenarios for the evaluation and validation depend 
heavily on the data flow inside the ACGT infrastructure, which in 
turn depend on the architecture retained. Figure 4 provides a 
less abstract (and somewhat simplified and hence easier to be 
understood by non-experts) description of the reference 
architecture. 
One important feature of this architecture is the isolation of the 
patients’ private information from the core of the ACGT 
environment described in the initial DoW; only properly 
anonymized data are allowed to flow outside the hospital (in the 
present context ‘hospital‘ refers to any institution legally housing 
the database containing identifiable patient information. 
In order to facilitate data access and implementation of legacy 
code in the ACGT environment without rewriting interfaces, an 
anonymized mirror of the clinical-trial databases is maintained. 
It is the latter that will be accessible to clinicians and 
researchers, once properly authenticated. 
Key bioinformatics and knowledge discovery 
services 
Heterogeneous biomedical database integration 
Distributed and heterogeneous databases, created in the 
context of multi-centric, post-genomic clinical trials on cancer, 
need to be easily accessible and transparently queried in the 
context of a user's discovery driven analytical tasks. A central 
challenge, therefore, to which ACGT needs to respond, is the 
issue of semantic integration of heterogeneous biomedical 
databases. 
The process of heterogeneous database integration may be 
defined as ‘the creation of a single, uniform query interface to 
data that are collected and stored in multiple, heterogeneous 
databases’.  Several varieties of heterogeneous database 
integration are useful in biomedicine. The most important ones 
are: 
1. Vertical integration: the aggregation of semantically similar 
data from multiple heterogeneous sources. For example, a 
‘virtual repository’ that provides homogeneous access to clinical 
data that are stored and managed in databases across a 
regional health information network is reported in [16, 17, 18]. 
2. Horizontal integration: the composition of semantically 
complementary data from multiple heterogeneous sources. For 
example, systems that support complex queries across 
genomic, proteomic and clinical information sources for 
molecular biologists are reported in [19, 20, 21]. 
Typical examples of research projects addressing the issue of 
heterogeneous biomedical database integration are the 
TAMBIS (Transparent Access to Multiple Bioinformatics 
Information Sources) [19] Project, which creates a 
bioinformatics domain ontology by using the GRAIL Description 
Logic Language. Mapping concepts to existing information 
sources, queries against the ontology are evaluated by 
accessing individual sources in a user-transparent manner. 
Although this approach is novel, scalability and expressivity are 
a concern. Also, the depth and quality of the TAMBIS ontology, 
or its overlap with existing biomedical ontologies, such as the 
gene ontology, are difficult to evaluate because the ontology 
contents are not contributed currently to a source, such as 
UMLS or other. 
Also, an information mediator prototype, called KIND 
(knowledge-based integration of neuroscience data) [21], has 
been developed as part of an integrated neuroscience 
workbench project at SDSC/UCSD within the NPACI project 
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Figure 5: The data-access architecture. 
(National Partnership for Advanced Computational 
Infrastructure,  http://www.npaci.edu). The broad goal of the 
workbench is to serve as an environment where, among other 
tasks, the neuroscientist can query a mediator to retrieve 
information from across a number of information sources, and 
use the results to perform her own analysis on the data. 
In ACGT, we have adopted an ontology-based approach to the 
integration challenge [22]. As a result, two services become of 
paramount importance in our architecture; the Master Ontology 
on Cancer and the Mediator Service. These are briefly 
discussed in the next sections. 
The data-access architecture 
As said previously, the ACGT data-access architecture is 
composed of a set of key services, namely the ACGT-DAS, the 
ACGT-SM, the ACGT-MO and some additional dedicated tools. 
While the first two services provide the means to resolve 
syntactic and semantic heterogeneities when accessing 
heterogeneous databases, the latter acts as a core resource 
supporting the data-integration process. Figure 5 presents the 
detailed data-access architecture in ACGT, showing the 
interactions between these three main services. 
The following sections explain in more detail the various issues 
faced in the implementation of the ACGT-MO and the ACGT-
DAS and the ACGT-SM services. 
The ACGT Master Ontology (MO) on Cancer 
The ACGT Consortium chose ontologies as the main 
knowledge representation (KR) tool in order to represent the 
relevant parts of medical knowledge gathered along the years 
by cancer researchers and clinicians involved with the theory 
and practice of oncology. We will not spend much time here 
debating the advantages of ontologies versus other KR 
strategies, since we trust that this has been covered elsewhere 
in the relevant literature [23, 24, 25]. We simply believe that 
biomedicine is one of the research fields that stands to benefit 
greatly from the ‘ontological turn’, as can be seen from the 
ACGT project. 
Among the challenges of the ACGT MO development, the large 
scope of the project was certainly the most demanding. Many 
areas, such as clinical studies, clinical cancer management and 
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care, genomic research, etc, had to be reflected; all these, on 
the other hand, could easily make the subject of a plethora of 
more focused and targeted domain ontologies, wherefrom, 
ideally, the ACGT MO might be constructed in a modular 
manner. That, unfortunately, could not happen, be it for the 
simple fact that no such targeted ontologies exist yet, or are not 
in a consistent shape to meet the quality demands of the ACGT 
consortium. ACGT-partner IFOMIS (http://www.ifomis.uni-
aarland.de/) is active in numerous international efforts aimed at 
developing cutting-edge ontologies. The ontology for biomedical 
investigation (OBI), for example is an ontology that ‘will support 
the consistent annotation of biomedical investigations, 
regardless of the particular field of study’ [26]. 
In particular, and quite remarkably, the section of the OBI 
dubbed the ‘ontology of clinical investigation—OCI’ 
(http://groups.google.com/group/OCInv) turns out to be covering 
part of the domain presently embraced by the ACGT MO. Given 
that ACGT researchers deal, at the present time, on both fronts, 
we expect not mere compatibility, but a great deal of integration 
and convergence between these parallel efforts, to the point 
where, upon attaining a reasonable degree of stability, we 
envisage importing the OCI (as well as some other relevant 
branches of the OBI) into the ACGT MO. The modular character 
of MO is also reflected via the use of FMA [27] and GO [28]. 
We, nevertheless, still like to regard the ACGT MO as a single-
domain ontology, as this is likely to guarantee a uniform 
treatment of the issues covered by the ACGT umbrella. 
In order to provide a consistent and sound representation, the 
ACGT MO employs the resources of a top-level ontology or 
upper-level ontology, which is, according to the Standard Upper 
Level Ontology Working Group of IEEE, ‘limited to concepts that 
are meta, generic, abstract and philosophical and therefore are 
general enough to address (at a high level) a broad range of 
domain areas. Concepts specific to given domains will not be 
included; however, this standard will provide a structure and a 
set of general concepts upon which domain ontologies (e.g. 
medical, financial, engineering) could be constructed’ [29]. We 
have chosen the Basic Formal Ontology (BFO) 
(http://www.ifomis.uni-saarland.de/bfo/) as top level for the 
ACGT MO, since BFO has proven to be highly applicable to the 
biomedical domain [30]. The ACGT Master Ontology, hence, 
inherits BFO's foundational principles: realism (ontologies as 
representations of reality rather than concrete specifications of 
conceptual schemes), perspectivalism (many equally valid 
perspectives on reality), fallibilism (our ontologies are fallible 
and perpetually evolving), and adequatism (no emphasis on 
reducing the various ontological categories to few basic ones) 
(readers are referred to the BFO manual [31] for detailed 
explanations). 
The ACGT MO is presented as an .owl file and is written in 
OWL-DL. It was built, and is being maintained/curated, using 
the Protégé-OWL free open-source ontology editor 
(http://protege.stanford. edu/). 
The process that gave rise to the present state of the 
representation of clinical reality was rather convoluted and 
highly elaborate, requiring multiple recurring steps and a 
multifaceted approach. Firstly, actual case report forms (CRFs) 
from ACGT trials were collected and analysed with respect to 
the universals (classes) more-or-less explicitly present in the 
information gathered. In parallel, basic aspects of cancer 
pathology and cancer management were studied by our 
researchers. The outcome of these activities provided the basic 
information on the universals and relations (properties) captured 
in the ACGT MO. This ontology prototype was made available 
to all partners in the project. In addition, clinical partners were 
asked to review the prototype with respect to clinical accuracy 
and technical partners for reviews on the usability. Based on the 
results of these reviews, the ontology was refined step by step, 
keeping up the collaboration with all partners in the consortium 
and asking for their constant review of results. 
The data-access services (ACGT-DAS) 
The data-access layer (shown in Figure 4) is implemented 
through the appropriate services, the data-access services 
(ACGT-DAS in Figure 5). They provide a uniform data-access 
interface. This includes uniformity of transport protocol, 
message syntax, query language and data format. They are 
also used for exporting the structure of the database, using a 
common data model, together with possible query limitations of 
the data source. Finally, since strict legal and ethical 
requirements with respect to data access exist that need to be 
adhered to, they enforce the data source access policy, and 
audit access to data sources. For the first implementation, we 
focused our effort on the first requirement, so that integration 
with the ACGT-SM, using test databases, could start as soon as 
possible. 
Web services have been chosen as the common interface 
technology within ACGT, as this technology suits the distributed 
nature of the project with respect to the data, computing 
resources and development teams. More specifically, the 
ACGT-DAS are implemented as OGSA-DAI services, a Web 
services framework for data access [32], which uses an activity 
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framework that enables flexible service invocation and reuse of 
common data-access functionality. 
We have implemented data-access services for two data source 
types: relational databases and medical image databases. 
These data sources have the benefit that there are established 
standards for data access, namely SQL/JDBC for relational 
databases, and DICOM for medical image databases. 
Currently, appropriate services are implemented for accessing 
other databases managing post-genomic data (metabolomics, 
proteomics, etc) as well as public biomedical databases. 
The semantic mediator (ACGT-SM) 
The semantic mediation process is realized by a set of tools that 
support the database integration process. The core component 
is the ACGT-SM, in charge of exposing the global schema, 
processing queries and retrieving integrated results. Its 
functionality is offered as a Web service to other components, 
that is knowledge discovery tools, the workflow editor, other 
specific end-user tools, etc. Additional components that are 
used for overcoming several issues in the data integration 
process, as discussed previously, are the mapping tool, the 
data cleaning module—for retrieved instances—and the query 
preprocessing module, for literal homogenization in queries. 
Technical description of the role and functions of these tools 
goes beyond the scope of the current paper. It suffices to say 
that the complex ‘semantic data integration’ tasks are 
addressed in the ACGT architecture through a family of 
interoperating generic and specific tools and services. 
A case study, based on the integration of two clinical trial 
databases, that is the SIOP and the TOP databases, filled with 
test data (actual patient data were avoided due to privacy 
issues) and a corresponding DICOM image database was 
performed. The sources were successfully integrated, and the 
schemas, that is the views representing the underlying 
databases, produced after the integration process, were 
validated by domain experts. This case study is fully 
documented in [33] and experiences are discussed in the 
following section. 
Knowledge discovery services 
Once these multi-level clinical and genomic data are integrated, 
they can be mined to extract new knowledge that can be useful 
in topics such clinical diagnosis, therapy, prevention and, of 
course, the design of new studies (such as in the case of 
ACGT, clinico-genomic trials). 
Knowledge discovery in clinico-genomic data presents a new 
array of challenges since it differs significantly from the original 
problems of data analysis that prompted the development of 
grid technologies, for example in particle physics and astronomy 
[9, 34]. The exploitation of semantics information in the 
description of data sources and data analysis tools is of high 
importance for the effective design and realization of knowledge 
discovery processes. Semantics are usually made concrete by 
the adoption of metadata descriptions and relevant 
vocabularies, classifications and ontologies. In ACGT, these 
semantics descriptions are managed by the grid infrastructure, 
and therefore the knowledge discovery services build and 
operate on a knowledge grid platform [35]. 
Workflows 
The Workflow Management Coalition (WFMC, 
http://www.wfmc.org/) defines a workflow as ‘The automation of 
a business process, in whole or part, during which documents, 
information or tasks are passed from one participant to another 
for action, according to a set of procedural rules’. In other 
words, a workflow consists of all the steps and the orchestration 
of a set of activities that should be executed in order to deliver 
an output or achieve a larger and sophisticated goal. In 
essence, a workflow can be abstracted as a composite service, 
that is a service that is composed of other services that are 
orchestrated in order to perform some higher level functionality. 
The aim of the ACGT workflow environment is to assist the 
users in their scientific research by supporting the ad hoc 
composition of different data access and knowledge extraction 
and analytical services into complex workflows. This way the 
users can extend and enrich the functionality of the ACGT 
system by reusing existing ACGT compliant services and 
producing ‘added value’ composite services. This reuse and 
composition of services is in some sense a programming task 
where the user actually writes a program to realize a scenario or 
to test a scientific hypothesis. 
In order to support the ACGT users to build and design their 
workflows, a visual workflow-programming environment has 
been designed (Figure 6). It is a Web-based workflow editor and 
designer that is integrated into the rest of ACGT system so as to 
take advantage of the grid platform and the ACGT specific 
infrastructure and services. In particular, this workflow designer 
features a user-friendly graphical user interface (GUI) that 
supports the efficient browsing and searching of the available 
ACGT services and their graphical interconnection and 
manipulation to construct complex scientific workflows. The 
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Figure 6: A typical layout of the ACGT workflow designer that allows users, through the ACGT portal, to design and execute their scientific 
explorations by seamlessly integrating the various data access services and analytical tools in what we refer to as ‘discovery workflows’. 
 
choice of a graphical representation of the workflow and the 
support for 'point-and-click' handling of the workflow graph was 
made on the basis that this is more intuitive for the users and 
increases their productivity. Additional features that also take 
advantage of the metadata descriptions of services include the 
validation in the design phase of the workflows in order to 
reduce or even eliminate the incorrect combination of 
processing units and the provision of a ‘service 
recommendation’ functionality based on the data types and data 
formats of inputs and outputs and are currently under 
development. 
The architecture of the workflow environment also includes a 
server side component for the actual execution (‘enactment’) of 
workflows. Each workflow is deployed as a ‘higher order’, 
composite service and the workflow enactor is the grid-enabled 
component responsible for the invocation, monitoring and 
management of running workflows. The standard workflow 
description language WS-BPEL [36] has been selected as the 
workflow description format and being a standard it enables the 
separation of the workflow designer from the workflow enactor 
and facilitates their communication and integration: the designer 
is a ‘rich internet application’ running inside the users' browsers 
that stores the workflows in WS-BPEL format into a workflow-
specific repository, whereas the enactor is an ACGT service 
running into the ACGT grid that ‘revitalizes’ the persisted 
workflows as new services. 
Data, service and workflow metadata 
Easy integration of applications and services requires 
substantial meta-information on algorithms and input/output 
formats if tools are supposed to interoperate. Furthermore, 
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assembly of tools into complex ‘discovery workflows’ will only be 
possible if data formats are compatible and semantic 
relationships between objects shared or transferred in 
workflows are clear. In achieving such requirements, the use of 
meta-data is important. As a result, in ACGT we focus on the 
systematic adoption of metadata to describe grid resources, to 
enhance and automate service discovery and negotiation, 
application composition, information extraction and knowledge 
discovery [37]. Metadata is used in order to specify the concrete 
descriptions of things. These descriptions aim to give details 
about the nature, intent, behaviour, etc, of the described entity, 
but they are also data that can be managed in the typical ways 
so this explains the frequently used definition: ‘metadata are 
data about data’. 
Examples of this data may be research groups, participating in 
a CT and publishing the datasets, data types that are being 
exposed, analytical tools that are published, the input data 
format required by these tools and the output data produced 
and so forth. Some of types of metadata that have been 
identified are as follows: 
1. Contact info: contact info and other administrative data about 
a site participating in a CT who shares information on the grid. 
2. Data type: the data type that a site is exposing and the 
context upon which this data were generated. 
3. Data collection method: this would include the name of the 
technique or the platform that was used to perform the analysis 
(e.g. Affymetrix), its model and software version, etc. 
4.  Ontological category: an ontological category describes a 
particular concept that the dataset exposes or a tool operates 
upon. 
Analytical services metadata 
Similarly, the identified analytical services' metadata 
descriptions fall into the following categories: 
1. the task performed by the service; that is the typology of the 
analytical data analysis process (e.g. feature/gene selection, 
sample/patient categorization, survival analysis); 
2. the  steps composing the task and the order in which the 
steps should be executed; 
3. the method used to perform an analytical/bioinformatics task; 
4. the algorithm implemented by the service; 
5. the input data on which the service works; 
6. the kind of output produced by the service. 
Our ultimate challenge is to achieve the implementation of 
semantically aware grid services. In achieving this objective, a 
service ontology is being developed to provide a single point of 
reference for these concepts and to support reasoning of 
concept expressions. 
 
Creating and sharing ACGT compliant services 
Achieving the level of automation, that is graphically depicted in 
Figure 6, requires the creation of highly interoperable services. 
Creating a service involves describing, in some conventional 
manner, the operations that the service supports; defining the 
protocol used to invoke these operations over the internet and 
operating a server to process incoming requests. 
Although a fair amount of experience has been gained with the 
creation of services and applications in different science 
domains, significant problems do still remain, especially with 
respect to interoperability, quality control and performance. 
These are issues to which ACGT focuses, and these are briefly 
discussed in the next subsections. 
Interoperability and reuse 
Services have little value if others cannot discover, access and 
make sense of them. Yet, as Stein has observed [38], today's 
scientific communities too often resemble medieval Italy's 
collection of warring city, states, each with its own legal system 
and dialect. Available technological (i.e. Web services) 
mechanisms for describing, discovering, accessing and 
securing services provide a common alphabet, but a true lingua 
franca requires agreement on protocols, data formats and 
ultimately semantics. In the ACGT project, we are paying 
particular attention on these issues and especially on the issue 
of semantics (see section on metadata). 
Management 
In a networked world, any useful service will become 
overloaded. Thus, we need to control who uses services and for 
what purposes. Particularly, valuable services may become 
community resources requiring coordinated management. Grid 
architectures and software—a set of Web services technologies 
focused on distributed system management—can play an 
 13  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h
 
A
r
t
i
c
l
e
 ecancer 2007, 1:56 
 
 
Figure 7: Overview of the ACGT data protection framework: actors and interactions. 
important role in this regard [39], and ACGT is focusing on 
exploiting these opportunities made available by grid computing. 
Quality control 
As the number and variety of services grow and 
interdependencies among services increase, it becomes 
important to automate previously manual quality control 
processes—so that, for example users can determine the 
provenance of a particular derived data product [40]. The ability 
to associate metadata with data and services can be important, 
as can the ability to determine the identity of entities that assert 
metadata, so that consumers can make their own decisions 
concerning quality. 
 
The ACGT security framework 
We recognise that the sharing of multi-level data outside the 
walls of a hospital or a research organization generates 
complex ethical and legal issues. It is also well known that the 
concerns around ‘security issues’ have been one of the major 
obstacles that have inhibited wider adoption of information 
technology solutions in the healthcare domain. As a result, we 
have devoted significant efforts in the study and analysis of the 
ethical and legal issues related to cross-institutional sharing of 
post-genomic datasets and have defined every aspect, both 
technical and procedural, of the required security framework. It 
is worth mentioning at this stage that security and privacy are 
active areas of research, and technologies are emerging that 
are fully utilized in ensuring the highest possible level of security 
of the ACGT platform. 
Based on such an approach we concluded that trust and 
security must to be addressed at multiple levels; these include 
(a) infrastructure, (b) application access, (c) data protection, (d) 
access control, which would be policy governed and (e) privacy-
enhancing technology, such as de-identification. 
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The European Directive on Data Protection [41] deals with the 
protection of personal data and imposes many restrictions on its 
use. In order to allow ACGT partners to handle and exchange 
medical data in conformance with the requirements of European 
Directive on Data Protection, an advanced data protection 
framework has been designed. This framework (illustrated in 
Figure 7) achieves this goal through an integrated approach that 
includes technical requirements but also policies and 
procedures (for more details see [8], Post-genomic clinical 
trials—the perspective of ACGT, in the same issue of this 
journal). Some of the aspects of the data protection framework 
are (a) anonymization or pseudonymzation of the data, (b) a 
trusted third party (TTP) pseudonymization and a corresponding 
pseudonymization tool, (c) technology-supported measures to 
control the anonymity context, (d) an ACGT data protection 
board (acting as a TTP) responsible for issuing credentials for 
data access to authorized users and (e) definition of the 
necessary consent forms and legal agreements that need to be 
signed by all members of any ACGT Virtual Organization. 
Description of the technical details of the security architecture of 
ACGT (the data protection framework) goes beyond the scope 
of the current article. Nevertheless, the main message that we 
want to stress is the fact that a well designed set of both 
technological as well as procedural measures have been taken, 
so that a high degree of trust and security is built into the final 
infrastructure to be delivered. 
Discussion and outlook 
In this paper, we consider a world where biomedical software 
modules and data can be detected and composed to define 
problem-dependent applications. We wish to provide an 
environment allowing clinical and biomedical researchers to 
search and compose bioinformatics and other analytical 
software tools for solving biomedical problems. We focus on 
semantic modelling of the requirements of such applications 
using ontologies. 
The objective of this article is not so much to describe in detail 
the technological aspects of the infrastructure being developed. 
Rather, our objective is to present the vision behind our work, to 
reveal the anticipated benefits for cancer research and to 
present the main technological challenges we are addressing. 
At the same time, we seek to interact, at this early stage of our 
implementation plan, with the widest possible community of our 
future users with the objective of crystallizing requirements and 
ensuring that we are indeed responding to real user needs. 
The project has conceived an overall architecture for an 
integrated biomedical sciences platform. The infrastructure 
being developed uses a common set of services and service 
registrations for the entire clinical trial on cancer community. We 
are currently focusing on the development of the core set of 
components up to a stage where they can effectively support in 
silico investigation. Initial prototypes have been useful in 
crystallizing requirements for semantics. 
The project has set up cross-disciplinary task forces to propose 
guidelines concerning issues related to data sharing, for 
example legal, regulatory, ethical and intellectual property, and 
is developing enhanced standards for data protection in a Web 
(grid) services environment. 
In addition, the project is developing: 
1.  standards and models for exposing Web services 
(semantics), scientific services, and the properties of data 
sources, datasets, scientific objects, and data elements; 
2.  new, domain-specific ontologies, built on established 
theoretical foundations and taking into account current 
initiatives, existing standard data representation models and 
reference ontologies; 
3. innovative and powerful data exploitation tools, for example 
multi-scale modelling and simulation, considering and 
integrating from the molecular to the systems biology level and 
from the organ to the living organism level; 
4. standards for exposing the properties of local sources in a 
federated environment; 
5. a biomedical grid infrastructure offering mediation services for 
sharing data and data-processing methods and tools; 
6.  advanced security tools including anonymization and 
pseudonymization of personal data according to European legal 
and ethical regulations; 
7.  a Master Ontology on Cancer and use of standard clinical 
and genomic ontologies and metadata for the semantic 
integration of heterogeneous databases; 
8.  an ontology-based trial builder for helping to easily set up 
new clinico-genomic trials, to collect clinical, research and 
administrative data and to put researchers in the position to 
perform cross-trial analysis; 
9.  data-mining services in order to support and improve 
complex knowledge discovery processes; 
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10.  an easy-to-use workflow environment, so that biomedical 
researchers can easily design their ‘discovery workflows’ and 
execute them securely on the grid.  
A range of demonstrators, stemming from the user-defined 
scenarios, together with these core set of components will 
enable us to both begin evaluation and gather additional and 
more concrete requirements from our users. These will allow us 
to improve and refine the facilities of the ACGT services. 
 
Community involvement 
ACGT's vision is to become a pan-European voluntary network 
connecting individuals and institutions to enable the sharing of 
data and tools and thereby creating a European-wide Web of 
cancer clinical research. The project promotes the principle of 
open source and open access, thus enabling the gradual 
creation of a European Biomedical Grid on Cancer. Hence, the 
project plans to introduce additional clinical trials during its 
lifecycle. 
It is our strong belief that the project will not fully attain its 
objectives unless it succeeds in attracting the involvement of the 
user communities, that is clinical and research centres active in 
post-genomic cancer research. 
It is, therefore, our objective to devise mechanisms to allow the 
community to engage in a bio-directional dialogue with us. 
Currently, the project website (www.eu-acgt.org) provides a 
limited set of such mechanisms, which will be extended and 
enriched as the project matures. We invite the clinical research 
community on cancer to join us in the effort to realize the vision 
that lies behind the project, that is automation of the biomedical 
knowledge discovery process. 
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